+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Antimigraine Market: Therapeutic Drugs, Diagnostics and Medical Devices Strategic Analysis to 2022 in the United States, the United Kingdom and Germany

  • PDF Icon

    Report

  • 634 Pages
  • September 2019
  • Region: Germany, United States
  • CR Life Science SC
  • ID: 5323769
Description Jump to:

The Most Complete Market Report in the Treatment of Migraine for the United States, United Kingdom and Germany

A profitable market for biopharmaceutical and medical devices companies in the long-term

The market to treat migraine is based on treating patients’ symptoms without any prospect of a near future cure, which generates considerable revenues for the companies involved. Scientific advances, new technologies and innovative products in the pipeline make the treatment of migraine a promising and profitable market with interesting opportunities in the coming years.

Drivers and restraints coming from different factors will modulate the anti-migraine market in the United States, United Kingdom and Germany

Legislation and regulatory affairs, market participants, economic environment and end users, among other factors, act as drivers and restraints that modulate the market. Possible changes to all these drivers and restraints have been carefully analysed to measure the potential impact on this market.

A holistic view properly structured to better understand the anti-migraine market

The purpose of this report is to give a holistic view as accurately as possible of the total antimigraine market. It is segmented by product type to facilitate the identification of similar competing products rather than competing companies. Revenues and forecasts have been calculated considering the most possible accurate use of these products in the treatment of migraines.

Antimigraine drugs properly segmented

The report is segmented into abortive and preventive drugs for the therapeutic drugs market. Subsegments include analgesics and antiemetics, specific antimigraine drugs, antihypertensive drugs, antidepressants, anticonvulsants, antiserotonergic drugs, botulinum toxins, and homeopathic products and herbs.

Anti-migraine medical devices properly segmented

For medical devices, it is segmented into biofeedback, neurostimulators and intraoral devices.

Patents as a source of information in the antimigraine market

Particular attention has been paid to patents as a source of state-of-the-art technology and intellectual property protection issues in this market.

Reasons to buy this report

  • Complete information about migraine.
  • Current treatments worldwide and particularly in the United States, United Kingdom and Germany. Therapeutic drugs and medical devices have been segmented to get an accurate picture of the market in order to establish better strategies.
  • Analysis of companies involved. Products portfolio and related intellectual property protection issues (patents).
  • Analysis for products in the pipeline. Companies involved and related intellectual property protection issues (patents). Revenue forecasts to 2022.
  • State-of-the-art technology. Opportunities and threats.
  • Size of the market and its segments. Revenues and revenue forecasts to 2022. Analysis of all factors affecting the market. Analysis of future trends that could affect the market and its segments.
  • Social, medical and end users’ trends.
  • Key unmet needs, opportunities and threats.

This report is of particular relevance for investors, venture capitalists, professionals from pharmaceutical and medical devices companies, scientists, trade press journalists, and in general any stakeholder with an interest in the antimigraine market.

The most complete market report in the treatment of migraine for the United States, United Kingdom and Germany

Migraine. Alternative therapies. Therapeutic drugs. Diagnostics. Medical Devices. Products in the pipeline. Regulatory and legal issues. Economics. Patents. Demographics and epidemiology. End users perceptions and social trends. Opportunities and threats. Market size and growth rates for products to 2022 in the United States, the United Kingdom and Germany.

Table of Contents

1. Executive Summary
1. A. The Antimigraine Market. Therapeutic Drugs, Diagnostics and Medical Devices Strategic Analysis to 2022 in the United States, the United Kingdom and Germany
2. Methodology. Primary and Secondary Research. Purpose of this Report and Forecasts
3. Introduction to the Industry and World Overview
3. A. Migraine and Cluster Headaches. Etiology and Pathogenesis.
3.A.1. Alternative Therapies
3.B. Antimigraine Drugs
3.B.1. Antimigraine Drugs Types
3.B.1.I. Abortive Drugs
3.B.1.I.a. Analgesics and Antiemetics
3.B.1.I.b. Specific Antimigraine Drugs
3.B.1.I.b.1. Triptans
3.B.1.I.b.2. Ergot Alkaloids
3.B.1.I.b.3. Isometheptene Mucate
3.B.1.I.b.4. Antiemetic combinations
3.B.1.I.b.5. Tolfenamic acid
3.B.1.II. Preventive Drugs
3.B.1.II.a. NSAIDs
3.B.1.II.b. Antihypertensive Drugs
3.B.1.II.b.1. Beta-blockers
3.B.1.II.b.2. Calcium channel blockers
3.B.1.II.b.3. Clonidine
3.B.1.II.b.4. Angiotensin-converting enzyme (ACE) inhibitors
3.B.1.II.c. Antidepressants
3.B.1.II.c.1. Tricyclic antidepressants
3.B.1.II.c.2. Selective Serotonin Re-uptake Inhibitors (SSRIs)and Serotonin-norepinephrine Re-uptake Inhibitors (SNRIs)
3.B.1.II.c.3. Lithium
3.B.1.II.d. Anticonvulsants
3.B.1.II.e. Anti-serotonergic Drugs
3.B.1.II.f. NMDA receptor antagonists
3.B.1.II.f.1. Memantine
3.B.1.II.g. Botulinum Toxins
3.B.1.II.h. Homeopathic products and Herbs
3.C. Antimigraine Diagnostic Products
3.C.1. Migraine Classification
3.C.2. Diagnostic Tools
3.C.3. Genetic testing for Migraine
3.D. Antimigraine Devices
3.E. The Antimigraine Industry
3.E.1. Therapeutic Drugs
3.E.2. Diagnostic Products
3.E.3. Medical Devices
3.F. Industry Issues
3.F.1. Global Economic Issues
3.F.1.I. Antimigraine Health Economics
3.F.1.I.a. The meaning of Pharmacoeconomics
3.F.1.I.b. Cost of migraine
3.F.1.I.c. Antimigraine Drugs Cost-of-Treatment and Pharmacoeconomic Facts
3.F.1.I.c.1. Abortive drugs
3.F.1.I.c.2. Preventive drugs
3.F.1.I.d. Migraine Diagnostics Costs
3.F.1.I.e. Antimigraine Medical Devices Costs
3.F.2. Antimigraine Research and Development Issues
3.F.2.I. Biomarkers and Migraine Genetics
3.F.2.I.a. The Future of Biomarkers and Genetic Testing
3.F.2.I.b. Gene therapy and CRISPR technology
3.F.2.II. Other Lines of Research
3.F.2.III.a. Therapeutic Drugs
3.F.2.III.a.1. Therapeutic Drugs in the pipeline
3.F.2.III.b. Diagnostic Products
3.F.2.III.b.1. Diagnostic Products in the pipeline
3.F.2.III.c. Medical Devices
3.F.2.III.c.1. Medical Devices in the pipeline
3.F.3. Manufacturing Trends
3.F.3.I. Antimigraine Drugs Formulations and Preparation Processes
3.F.4. Regulatory and Legal Issues
3.F.4.I. Regulatory and Legal Issues in Therapeutic Drugs
3.F.4.I.a. United States
3.F.4.I.b. European Union
3.F.4.II. Regulatory and Legal Issues in Diagnostic Products
3.F.4.II.a. United States
3.F.4.II.b. European Union
3.F.4.III. Regulatory and Legal Issues in Medical Devices
3.F.4.III.a. United States
3.F.4.III.b. European Union
3.F.5. Patent Protection Issues
3.F.5.I. International Patent Law
3.F.5.I.a. Relevant Patent Legislation Affecting Healthcare Products
3.F.5.I.b. Biotech Patents
3.F.5.II. Patents on Antimigraine Therapeutic Drugs
3.F.5.II.a. Patents on Marketed Antimigraine Drugs
3.F.5.II.b. Patents on New Therapeutic Drugs
3.F.5.III. Patents on Antimigraine Diagnostic Products
3.F.5.III.a. Patents on Marketed Antimigraine Diagnostic Products
3.F.5.III.b. Patents on New Antimigraine Diagnostic Products
3.F.5.IV. Patents on Antimigraine Medical Devices
3.F.5.IV.a. Patents on Marketed Antimigraine Medical Devices
3.F.5.IV.b. Patents on New Antimigraine Medical Devices
3.F.5.V. Partnerships and license agreements opportunities
3.F.6. Demographics and Epidemiology
3.F.6.I. Statistical facts and quantitative analysis in a sample of 11 867 subjects
3.F.7. End users perceptions and social trends
3.F.8. Antimigraine market related therapeutic areas

4. Forecasts of the United States Antimigraine Market
4.A. Health and Welfare
4.A.1. Regulatory and Legal Issues
4.A.1.a. Therapeutic Drugs
4.A.1.b. Diagnostic Products
4.A.1.c. Medical Devices
4.A.1.d. Possible changes in legislation
4.A.2. Patent Legislation
4.A.3. Demographics and Epidemiology
4.A.4. End users perceptions and social trends
4.A.5. Economic Issues
4.A.6. Distribution channels
4.B. Forecasts of the Total Antimigraine Therapeutic Drugs Market in the United States
4.B.1. Competitive Analysis, Market Share and Trends
4.B.2. Revenues and Revenue Growth Rates
4.B.3. Pricing Trends
4.C. Forecasts of the Abortive Antimigraine Drugs Market in the United States
4.C.1. Competitive Analysis, Market Share and Trends
4.C.2. Revenues and Revenue Growth Rates
4.C.3. Pricing Trends
4.D. Forecasts of the Preventive Antimigraine Drugs Market in the United States
4.D.1. Competitive Analysis, Market Share and Trends
4.D.2. Revenues and Revenue Growth Rates
4.D.3. Pricing Trends
4.E. Forecasts of the Total Antimigraine Diagnostics Products Market in the United States
4.E.1. Competitive Analysis, Market Share and Trends
4.E.2. Revenues and Revenue Growth Rates
4.E.3. Pricing Trends
4.F. Forecasts of the Total Antimigraine Devices Market in the United States
4.F.1. Competitive Analysis, Market Share and Trends
4.F.2. Revenues and Revenue Growth Rates
4.F.3. Pricing Trends
5. Forecasts of the United Kingdom Antimigraine Market
5. A. Health and Welfare
5.A.1. Regulatory and Legal Issues
5.A.1.a. Therapeutic Drugs
5.A.1.b. Diagnostic Products
5.A.1.c. Medical Devices
5.A.2. Patent Legislation
5.A.3. Demographics and Epidemiology
5.A.4. End users perceptions and social trends
5.A.5. Economic Issues
5.A.6. Distribution channels
5.A.7. Brexit implications
5.B. Forecasts of the Total Antimigraine Therapeutic Drugs Market in the United Kingdom
5.B.1. Competitive Analysis, Market Share and Trends
5.B.2. Revenues and Revenue Growth Rates
5.B.3. Pricing Trends
5.C. Forecasts of the Abortive Antimigraine Drugs Market in the United Kingdom
5.C.1. Competitive Analysis, Market Share and Trends
5.C.2. Revenues and Revenue Growth Rates
5.C.3. Pricing Trends
5.D. Forecasts of the Preventive Antimigraine Drugs Market in the United Kingdom
5.D.1. Competitive Analysis, Market Share and Trends
5.D.2. Revenues and Revenue Growth Rates
5.D.3. Pricing Trends
5.E. Forecasts of the Total Antimigraine Diagnostics Products Market in the United Kingdom
5.E.1. Competitive Analysis, Market Share and Trends
5.E.2. Revenues and Revenue Growth Rates
5.E.3. Pricing Trends
5.F. Forecasts of the Total Antimigraine Devices Market in the United Kingdom
5.F.1. Competitive Analysis, Market Share and Trends
5.F.2. Revenues and Revenue Growth Rates
5.F.3. Pricing Trends
6. Forecasts of the German Antimigraine Market
6.A. Health and Welfare
6.A.1. Regulatory and Legal Issues
6.A.1.a. Therapeutic Drugs
6.A.1.b. Diagnostic Products
6.A.1.c. Medical Devices
6.A.2. Patent Legislation
6.A.3. Demographics and Epidemiology
6.A.4. End users perceptions and social trends
6.A.5. Economic Issues
6.A.6. Distribution channels
6.B. Forecasts of the Total Antimigraine Therapeutic Drugs Market in Germany
6.B.1. Competitive Analysis, Market Share and Trends
6.B.2. Revenues and Revenue Growth Rates
6.B.3. Pricing Trends
6.C. Forecasts of the Abortive Antimigraine Drugs Market in Germany
6.C.1. Competitive Analysis, Market Share and Trends
6.C.2. Revenues and Revenue Growth Rates
6.C.3. Pricing Trends
6.D. Forecasts of the Preventive Antimigraine Drugs Market in Germany
6.D.1. Competitive Analysis, Market Share and Trends
6.D.2. Revenues and Revenue Growth Rates
6.D.3. Pricing Trends
6.E. Forecasts of the Total Antimigraine Diagnostics Products Market in Germany
6.E.1. Competitive Analysis, Market Share and Trends
6.E.2. Revenues and Revenue Growth Rates
6.E.3. Pricing Trends
6.F. Forecasts of the Total Antimigraine Devices Market in Germany
6.F.1. Competitive Analysis, Market Share and Trends
6.F.2. Revenues and Revenue Growth Rates
6.F.3. Pricing Trends
7. Strategies, Tactics and Challenges for Success8. List of Companies and Institutions Mentioned in this Report9. AcronymsAppendix
List of Figures
3.A. Figure 1. Migraine, tension headache and cluster headache
3.A. Figure 2. Flow of electrical impulses and inflamed blood vessel
3.A. Figure 3. Nerves branching off the brainstem
3.A. Figure 4. The circle of Willis
3.A. Figure 5. Trigeminal nerve nucleus and brainstem.
3.A. Figure 6. Migraine center
3.A. Figure 7. Vessel dilation
3.D. Figure 9. Clinical Vagus Nerve Stimulation
3.D. Figure 10. Trigeminal nerve and its branches
3.D. Figure 11. NTI-tss devices
3.E.1. Figure 12. Therapeutic Drugs Industry Stakeholders
3.E.1. Figure 13. 2001-2015 Revenues of the Worldwide Pharmaceutical Market
3.E.1. Figure 14. Allocation of R&D investments by function (%)
3.E.2. Figure 15 Diagnostics Industry Stakeholders
3.E.3. Figure 16. Medical Devices Industry Stakeholders
3.F.1. Figure 17. USD/GBP Exchange rates in 1 August 2016-31 December 2016
3.F.1. Figure 18. USD/EUR Exchange rates in 1 August 2016-31 December 2016
3.F.1.I.a. Figure 19. SF-36 example
3.F.1.I.b. Figure 20. Ability to work suffering from episodic migraine, chronic migraine and epilepsy
3.F.1.I.c. Figure 21. Impact of migraine in a patient’s life
3.F.1.I.c. Figure 22. Pricing and Reimbursement in the United Kingdom
3.F.2.III.a. Figure 23. Eising et al. Epigenetic proposed model
3.F.2.III.c.1. Figure 24. Implantable ONS device
3.F.2.III.c.1. Figure 25. Brain section. Migraine center
3.F.2.III.c.1. Figure 26. TENS device
3.F.2.III.c.1. Figure 27. Vestibular neuromodulation device
3.F.2.III.c.1. Figure 28. Dental appliance
3.F.2.III.c.1. Figure 29. PFO device
3.F.3. Figure 30. US$ - Indian Rupee exchange rate. May 2016-March 2017
3.F.4.III.a. Figure 31. Medical Devices approval process in the United States
3.F.6.I. Figure 32. Self-diagnosed migraineurs. Males and females
3.F.6.I. Figure 33. Medically diagnosed migraineurs. Males and females
3.F.6.I. Figure 34. Diagnosis. Self-diagnosed and medically diagnosed.
3.F.6.I. Figure 35. Alcohol consumption
3.F.6.I. Figure 36. Migraineurs chickenpox
3.F.6.I. Figure 37. Self-diagnosed migraineurs depression, bipolar disorder or schizophrenia
3.F.6.I. Figure 38. Medically diagnosed migraineurs depression, bipolar disorder or schizophrenia
3.F.6.I. Figure 39. Overall biosample population depression, bipolar disorder and schizophrenia
3.F.6.I. Figure 40. Overall biosample population anorexia nervosa
3.F.6.I. Figure 41. Medically diagnosed migraineurs anorexia nervosa
3.F.6.I. Figure 42. Overall biosample population posttraumatic stress disorder
3.F.6.I. Figure 43. Medically diagnosed migraineurs posttraumatic stress disorder
3.F.6.I. Figure 44. Self-diagnosed migraineurs IBD
3.F.6.I. Figure 45. Medically diagnosed migraineurs IBD
3.F.6.I. Figure 46. Overall biosample population IBD
3.F.6.I. Figure 47. Self-diagnosed migraineurs IBS
3.F.6.I. Figure 48. Medically diagnosed migraineurs IBS
3.F.6.I. Figure 49. Overall biosample population IBS
3.F.6.I. Figure 50. Self-diagnosed migraineurs lung disease
3.F.6.I. Figure 51. Medically diagnosed migraineurs lung disease
3.F.6.I. Figure 52. Overall biosample population lung disease
3.F.6.I. Figure 53. Self-diagnosed migraineurs allergies to drugs
3.F.6.I. Figure 54. Medically diagnosed migraineurs allergies to drugs
3.F.6.I. Figure 55. Overall biosample population allergies to drugs
3.F.6.I. Figure 56. Self-diagnosed migraineurs milk cheese intake
3.F.6.I. Figure 57. Medically diagnosed migraineurs milk cheese intake
3.F.6.I. Figure 58. Overall biosample population milk cheese intake
3.F.6.I. Figure 59. Self-diagnosed migraineurs thyroid disorders
3.F.6.I. Figure 60. Medically diagnosed migraineurs thyroid disorders
3.F.6.I. Figure 61. Overall biosample population thyroid disorders.
3.F.7. Figure 62. Antimigraine combination medications. Effectiveness, ease of use and satisfaction
3.F.7. Figure 63. Antimigraine abortive drugs. Effectiveness, ease of use and satisfaction
3.F.7. Figure 64. Antimigraine preventive drugs. Effectiveness, ease of use and satisfaction
4.A. Figure 65. 2016. Privately insured adults in families having problems paying medical bills
4.A. Figure 66. 2011-2016. Percent distribution of privately insured adults
4.A. Figure 67. 2010-2016. Percentage of persons under age 65 enrolled in a high-deductible health plan without a health savings account or in a consumer-directed health plan, among those with private health insurance coverage
4.A. Figure 68. 1997-2016. Percentage of children aged 0-17 years who were insured or had private or public coverage
4.A. Figure 69. 1997-2016. Percentage of adults who were uninsured or had private or public coverage
4.B.1. Figure 70. 2016 US Total Antimigraine Therapeutic Drugs Market. Percentage of drug categories
4.B.1. Figure 71. 2016 US Total Antimigraine Therapeutic Drugs Market. Percentage of drug categories
4.B.1. Figure 72. 2022 US Total Antimigraine Therapeutic Drugs Market. Percentage of drug categories
4.B.2. Figure 73. US Total Antimigraine Therapeutic Drugs Market (US$ million)
4.C.1. Figure 74. 2016 US Total Antimigraine Abortive Drugs. Percentage of drug categories
4.C.1. Figure 75. 2015 US Specific Antimigraine Drugs. Percentage of drug categories
4.C.1. Figure 76. 2022 US Total Antimigraine Abortive Drugs. Percentage of drug categories
4.C.2. Figure 77. US Total Antimigraine Abortive Drugs (US$ million)
4.D.1. Figure 78. 2016 US Total Antimigraine Preventive Drugs Market. Percentage of drug categories
4.D.1. Figure 79. 2022 US Total Antimigraine Preventive Drugs Market. Percentage of drug categories
4.D.2. Figure 80. US Total Antimigraine Preventive Drugs (US$ millions)
4.E.2. Figure 81. US Total Antimigraine Diagnostics Market (US$ million).
4.F.1. Figure 82. 2016 US Total Antimigraine Medical Devices Market. Percentage of products
4.F.1. Figure 83. 2022 US Total Antimigraine Medical Devices Market. Percentage of products
4.F.2. Figure 84. US Total Antimigraine Medical Devices Market (US$ million)
5.A.1.a. Figure 85. GBP/EUR exchange rates 1 October 2016 - 30 June 2017
5.A.5. Figure 86. Drugs Pricing and Reimbursement in the UK
5.B.1. Figure 87. 2016 Total UK Antimigraine Pharmaceuticals Market. Percentage of drug categories
5.B.1. Figure 88. 2022 Total UK Antimigraine Therapeutic Drugs Market. Percentage of drug categories
5.B.2. Figure 89. UK Total Therapeutic Drugs Market (US$ million)
5.B.3. Figure 90. Cost per item dispensed in England for CNS drugs
5.C.1. Figure 91. 2016 UK Antimigraine Abortive Market. Percentage of drug categories
5.C.1. Figure 92. 2016 Prescription-only and OTC Specific Antimigraine Drugs. Percentage of drug categories
5.C.1. Figure 93. 2016 Total UK Triptans Market. Percentage of triptans
5.C.1. Figure 94. 2016 UK Sumatriptan sales (England, Scotland, Wales and Northern Ireland)
5.C.1. Figure 95. 2016 Total UK Rizatriptan sales (England, Scotland, Wales and Northern Ireland)
5.C.1. Figure 96. 2022 UK Antimigraine Abortive Drugs. Percentage of drug categories
5.C.2. Figure 97. UK Total Antimigraine Abortive Drugs Market (US$ million)
5.C.2. Figure 98. 2013-2016 UK Triptans market (US$ million)
5.C.3. Figure 99. UK average cost per sumatriptan item
5.C.3. Figure 100. UK average cost per prescribed sumatriptan (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 101. UK average cost per almotriptan item
5.C.3. Figure 102. UK average cost per almotriptan item (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 103. UK average cost per eletriptan item
5.C.3. Figure 104. UK average cost per eletriptan item (England, Scotland, Wales and Northern Ireland).
5.C.3. Figure 105. UK average cost per frovatriptan item
5.C.3. Figure 106. UK average cost per frovatriptan item (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 107. UK average cost per naratriptan item
5.C.3. Figure 108. UK average cost per naratriptan item (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 109. UK average cost per rizatriptan item
5.C.3. Figure 110. UK average cost per rizatriptan item (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 111. UK average cost per zolmitriptan item
5.C.3. Figure 112. UK average cost per zolmitriptan item (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 113. UK average cost per tolfenamic acid item
5.C.3. Figure 114. UK average cost per tolfenamic acid item (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 115. UK average cost per isometheptene mucate item
5.C.3. Figure 116. UK average cost per isometheptene mucate (Midrid) item (England, Scotland, Wales and Northern Ireland)
5.C.3. Figure 117. UK average cost per ergotamine tartrate item
5.C.3. Figure 118. UK average cost per ergotamine tartrate item (England, Scotland, Wales and Northern Ireland)
5.D.1. Figure 119. 2016 UK Total Antimigraine Preventive Drugs Market. Percentage of drug categories
5.D.1. Figure 120. 2016 UK propranolol revenues market (England, Scotland, Wales and Northern Ireland)
5.D.1. Figure 121. 2016 UK topiramate revenues market (England, Scotland, Wales and Northern Ireland)
5.D.1. Figure 122. 2016 UK pizotifen revenues market (England, Scotland, Wales and Northern Ireland)
5.D.1. Figure 123. 2022 UK Total Antimigraine Preventive Drugs
5.D.2. Figure 123. 2022 UK Total Antimigraine Preventive Drugs. Percentage of drug categories
5.D.3. Figure 124. UK average cost per metoprolol item.
5.D.3. Figure 125. UK average cost per metoprolol item (England, Scotland, Wales and Northern Ireland)
5.D.3. Figure 126. UK average cost per nadolol item
5.D.3. Figure 127. UK average cost per nadolol item (England, Scotland, Wales and Northern Ireland)
5.D.3. Figure 128. UK average cost per propranolol item
5.D.3. Figure 129. UK average cost per propranolol item (England, Scotland, Wales, Northern Ireland)
5.D.3. Figure 130. UK average cost per clonidine item
5.D.3. Figure 131. UK average cost per clonidine item (England, Scotland, Wales, Northern Ireland)
5.D.3. Figure 132. UK average cost per topiramate item
5.D.3. Figure 133. UK average cost per topiramate item (England, Scotland, Wales, Northern Ireland)
5.D.3. Figure 134. UK average cost per pizotifen item
5.D.3. Figure 135. UK average cost per pizotifen item (England, Scotland, Wales, Northern Ireland)
5.D.3. Figure 136. UK average cost per Botox item
5.D.3. Figure 137. UK average cost per Botox item (England and Wales)
5.E.2. Figure 138. UK Total Antimigraine Diagnostics Market (US$ million)
5.F.1. Figure 139. 2016 UK Total Antimigraine Medical Devices Market. Percentage of products
5.F.1. Figure 140. 2022 UK Total Antimigraine Medical Devices Market. Percentage of products
5.F.2. Figure 141. UK Total Antimigraine Medical Devices Market (US$ million)
6.A. Figure 142. German Therapeutic Drugs Institutions
6.B.1. Figure 143. 2016 Germany Total Antimigraine Therapeutic Drugs Market. Percentages of abortive and preventive drugs
6.B.1. Figure 144. 2016 Antimigraine Therapeutic Drugs Market. Percentages of drug categories
6.B.1. Figure 145. 2022 Germany Antimigraine Therapeutic Drugs Market. Percentage of drug categories
6.B.2. Figure 146. Germany Total Therapeutic Drugs Market
6.C.1. Figure 147. 2016 German Abortive Antimigraine Drugs Market. Percentage of drug categories
6.C.1. Figure 148. 2016 German Triptans Market. Percentage of triptans
6.C.2. Figure 149. Germany Total Antimigraine Abortive Drugs Market (US$ million)
6.C.3. Figure 150. Germany average cost per diclofenac prescription (US$)
6.C.3. Figure 151. Germany average cost per ibuprofen prescription (US$)
6.C.3. Figure 152. Germany average cost per metoclopramide prescription (US$)
6.C.3. Figure 153. Germany average cost per codeine and paracetamol combination product prescription (US$)
6.C.3. Figure 154. Germany average cost per sumatriptan prescription (US$)
6.C.3. Figure 155. Germany average cost per rizatriptan prescription (US$)
6.C.3. Figure 156. Germany average cost per naratriptan prescription (US$)
6.C.3. Figure 157. Germany average cost per zolmitriptan prescription (US$)
6.D.1. Figure 158. 2016 Germany Preventive Antimigraine Drugs Market
6.D.1. Figure 159. 2022 Germany Preventive Antimigraine Drugs Market. Percentages of drug categories
6.D.2. Figure 160. Germany Preventive Antimigraine Drugs Market (US$ million)
6.D.3. Figure 161. Germany average cost per metoprolol prescription (US$)
6.D.3. Figure 163. Germany average cost per propranolol prescription (US$)
6.D.3. Figure 164. Germany average cost per flunarizine prescription (US$)
6.D.3. Figure 165. Germany average cost per topiramate prescription (US$)
6.D.3. Figure 166. Germany average cost per amitriptyline prescription (US$)
6.E.2. Figure 167. German Antimigraine Diagnostic Products Market (US$ million)
6.F.1. Figure 168. 2016 Germany Total Antimigraine Medical Devices Market. Percentage of products
6.F.1. Figure 169. 2022 Germany Total Antimigraine Medical Devices Market. Percentage of products
6.F.2. Figure 170. Germany Total Antimigraine Medical Devices Market (US$ million)



List of Tables
3.A. Table 1. Retrospective study of 1,750 patients
3.A. Table 2. Allodynia questionnaire
3.B. Table 3. Comparative table of OTC antimigraine medications in the United States, United Kingdom and Germany
3.B.1.I.a. Table 4. 2017. NSAIDs approved to treat migraine in the United States, United Kingdom and Germany
3.B.1.I.a. Table 5. 2017. Combination analgesics approved to treat migraine in the United States, United Kingdom and Germany
3.B.1.I.b.1. Table 6. 2017. Triptans indications in the United States, United Kingdom and Germany
3.B.1.I.b.1. Table 7. 2017. Available triptans forms in the United States, United Kingdom and Germany
3.B.1.II.b.1. Table 8. 2016-17. Beta-blockers approved for the prophylaxis of migraine in the United States, United Kingdom and Germany
3.B.1.II.g. Table 9. Botulinum toxins
3.B.1.II.h. Table 10. 2016. Herb extracts that are available in the United States, United Kingdom and Germany
3.F.1.I.a. Table 11. Effectiveness vs cost pharmacoeconomic grid
3.F.1.I.a. Table 12. Usual approach to direct costs
3.F.1.I.a. Table 13. Usual approach to indirect costs
3.F.1.I.a. Table 14. Framework to determine the value of a product
3.F.1.I.b. Table 15. Indicators for possible outcomes of a healthcare economic study in the treatment of migraine in the United States, United Kingdom and Germany
3.F.1.I.c.1. Table 16. Analgesics and antiemetics cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.1. Table 17. Clinical data pertaining bioavailability, plasma half-life and responses to pain relief for tolfenamic acid, diclofenac and naproxen sodium
3.F.1.I.c.1. Table 18. Specific antimigraine drugs cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.1. Table 19. Clinical data pertaining bioavailability, plasma half-life and responses to pain relief for the different triptans available in the market
3.F.1.I.c.1. Table 20. Effectiveness and side effects of Cafergot, rizatriptan and sumatriptan
3.F.1.I.c.1. Table 21. Ergotamine tartrate co-administered with caffeine bioavailability, plasma half-life and pain response
3.F.1.I.c.1. Table 22. Isometheptene mucate co-administered with caffeine bioavailability, plasma half-life and pain response
3.F.1.I.c.2. Table 23. Beta-blockers cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 24. Beta-blockers bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 25. Calcium-channel blockers cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 26. Calcium-channel blockers bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 27. Clonidine cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 28. Clonidine bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 29. Lisinopril cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 30. Lisinopril bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 31. Tricyclic antidepressants cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 32. Tricyclic antidepressants bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 33. SSRIs cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 34. SSRIs bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 35. Lithium cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 36. Anticonvulsants cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 37. Anticonvulsants bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects.
3.F.1.I.c.2. Table 38. Pizotifen cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 39. Pizotifen bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 40. Memantine cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 41. Memantine bioavailability, plasma half-life, scientific and clinical evidence, and adverse effects
3.F.1.I.c.2. Table 42. Botulinum toxins cost estimates in the United States, United Kingdom and Germany
3.F.1.I.c.2. Table 43. Homeopathic products and herbs cost estimates in the United States, United Kingdom and Germany
3.F.1.I.d. Table 44. Migraine diagnostics costs in the United States, United Kingdom and Germany
3.F.1.I.e. Table 45. Antimigraine medical devices costs
3.F.2.I. Table 46. Potential loci for migraine phenotypes
3.F.2.I.a. Table 47. Potential migraine biomarkers
3.F.2.III.a.1. Table 48. Therapeutic drugs relevant clinical trials conducted for the treatment of migraine since 2007, focusing particularly on the period 2014-2017
3.F.2.III.c.1. Table 49. Medical devices relevant clinical trials conducted for the treatment of migraine in the period 2007-2017
3.F.3.I. Table 50. Number of patent applications related to formulations and preparation processes for approved active ingredients to treat migraine in the United States, Europe and China
3.F.4.I. Table 51. Data exclusivity and market protection in the United States and the European Union
3.F.5.II.b. Table 52. Patents on new therapeutic drugs
3.F.5.III.a. Table 53. Patents on marketed antimigraine diagnostic products
3.F.5.III.b. Table 54. Patents on new antimigraine diagnostic products
3.F.5.IV.b. Table 55. Patents on new antimigraine medical devices
3.F.5.V. Table 56. 2017. Patents that could be useful for license agreements in the antimigraine market.
4.A. Table 57. 2016 United States The approximate number of persons enrolled in the different health insurance types and approximate percentage of prescription drugs spending
4.A.5. Table 58. 2017. Abbreviated coverage of selected sales tax rates by state
4.B.1. Table 59. 2016-2017 FDA-approved antimigraine therapeutic drugs
4.F.1. Table 60. 2016-2017 Medical devices approved to treat migraine in the United States
5.B.1. Table 61. 2016-2017 Licensed antimigraine therapeutic drugs in the UK
5.F.1. Table 62. 2016-2017 Medical devices approved to treat migraine in the United Kingdom
6.B.1. Table 63. 2016-2017 Therapeutic drugs approved for the treatment of migraine in Germany
6.B.3. Table 64. General guideline of stakeholders’ profit margins for prescription-only pharmaceuticals in Germany
6.F.1. Table 65. 2016-2017. Medical devices approved to treat migraine in Germany.







Samples

Loading
LOADING...

Executive Summary

Migraine is one of those complex diseases that is not properly understood yet. The disease as a whole affects a significant percentage of the total population and has an important social and economic impact on society. The antimigraine market is based on treating patients’ symptoms without any prospect for a future cure, which generates considerable revenues for companies involved. Scientific advances, new technologies and innovative products in the pipeline make the treatment of migraine a promising and profitable market with interesting opportunities that should benefit all stakeholders in the coming years. 

Doctors and scientists believe that the etiology of the disease can be so different that we should speak about migraine subtypes rather than just migraine. However, most of the therapeutic drugs and medical devices available on the market are often indicated just for migraine, acute migraine, chronic migraine, or migraine with or without aura, without discriminating further among the different subtypes. Whilst this has led to a big market in terms of volume and value where many products compete, it has not met at least half of patients needs, who remain unsatisfied. Additionally, a large proportion of people suffering from migraines remain undiagnosed, which enhances the potential prospects for this market. For this reason, the antimigraine market is full of opportunities for new products that may work well for a large number of patients, and threats for old ones. 

For those companies and people eager to enter this market we start with an introduction and overview of the disease and products used to get quickly familiarized with the rest of the report. All possible factors that affect the market performance now and in the future are considered in a holistic view to allow the reader to make better-informed decisions. 

This report contains primary and secondary research and analysis of the current and future market for therapeutic drugs, diagnostics and medical devices to 2022 for the treatment of migraine in the United States, the United Kingdom and Germany. The competitive structure, prices and shares of the different products approved by the respective health authorities to treat migraine will give the reader an adequate idea of the dimension of this market and how to tackle it. During the study we have tried to estimate the most possible accurate figures for the real manufacturers’ revenues generated to treat migraine for these products, also taking into account sales of products used off-label destined to treat this disease. As a consequence, comparative conclusions among these three important markets are also at hand. 

An approach to the different stakeholders involved in this market and their influence is properly explained. Payers (health authorities and insurance companies) exert an imperative pressure to cut costs with different measures, whilst doctors try to defend their freedom to treat and prescribe. Wholesalers and pharmacies do their best to keep their profit margins. Patients’ associations and individuals’ perceptions about products and different aspects of disease management are particularly considered. 

The healthcare industry is one of the most regulated industries. We have paid special attention to the regulatory and legal issues as it is vital to understand the present and future of the healthcare industry and thus the antimigraine market. 

Intellectual property pretends to defend companies’ and individuals’ interests protecting their products and know-how from competitors. Patents determine prices and access to products, therefore shaping the present and future of the market. Patents are also an excellent source of information to assess the current state-of-the-art and must be observed worldwide. A proper strategy for patents is almost compulsory, and for this reason we have included whole sections for patents that are or may be relevant for the development of the antimigraine market not only in the countries concerned but in the whole world. References to patents are also present along the report whenever these could be of particular interest and convenience. 

This report is of particular relevance for investors, venture capitalists, pharmaceutical and medical devices companies, CEOs and company presidents, product managers, marketing managers, market research managers, sales managers, R&D managers, business development managers, intellectual property department managers, scientists, trade press journalists, and in general any professional with an interest in the antimigraine market.


Companies Mentioned

  • 1A Pharma GmbH
  • AAH Part of Celesio AG.
  • Aalborg University
  • Abbott Laboratories
  • AbbVie Inc
  • AbZ Pharma GmbH
  • Academia Sinica
  • Achelios Therapeutics Inc
  • Aché Laboratórios Farmacêuticos, S
  • Acis Arzneimittel
  • Actavis plc
  • ADD Advanced Drug Delivery Technology AG
  • Addex Pharma SA
  • Adolor Corporation
  • Advanced Bionics AG
  • Advanced Neuromodulation Systems Inc
  • Aegis Therapeutics LLC
  • Afgin Pharma LLC
  • Ajanta Pharma Ltd
  • Akron Children’s Hospital
  • Albert Einstein Healthcare Network
  • Albion Capital Group LLP
  • Alder Biopharmaceuticals
  • AlderBio Holdings LLC
  • Alexza Pharmaceuticals Inc
  • Aliud Pharma GmbH
  • Allergan plc
  • Allevia Health Inc
  • Almatica Pharma Inc
  • Almirall S
  • Alphapharm Pty Ltd
  • Als Biopharma
  • Altergon Italia Srl
  • Alvogen Inc
  • Alza Corporation
  • Amadeus Capital Partners
  • Ambry Genetics
  • American Chiropractic Association
  • American Society of Regional Anesthesia
  • Amerilab Technologies
  • Amgen Inc
  • Amorepacific Corporation
  • AndRx Corporation
  • Ani Pharmaceuticals Inc
  • AOK Baden-Württemberg
  • Apotex Inc
  • APR Applied Pharma Research SA
  • Aptalis Pharmatech Inc
  • Aradigm Corporation
  • Aragon Pharmaceuticals Inc
  • Arakis Ltd
  • Aralez Pharmaceuticals Inc
  • Arbor Pharmaceuticals LLC
  • Arcana Dr
  • Ariel Pharmaceuticals, Inc
  • Ariston Pharmaceuticals
  • Arteaus Therapeutics, LLC
  • Arzneimittelwerk Dresden GmbH
  • Asta Medica
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Athena Diagnostics Inc
  • Aubrey Group
  • Aurimmed Pharma Inc
  • Aurobindo Pharma Ltd
  • Autonomic Technologies Inc
  • Avanir Pharmaceuticals, Inc
  • Avigen Inc
  • Axiogenesis AG
  • B.R.A.H.M.S. GmbH.
  • Banner Pharmacaps Inc
  • Barr Pharmaceuticals Inc
  • Bayer Vital GmbH Geschäftsbereich Pharma
  • Beijing Double Crane Pharmaceutical Company Ltd
  • BeneChill Inc.
  • Berolina Klinic
  • Bestway (Holdings) Ltd
  • Beth Israel Deaconess Medical Center
  • BHR Pharmaceuticals Ltd
  • Bial Portela & CA SA
  • Biodelivery Sciences International Inc
  • Biofrontera Discovery GmbH
  • Biohaven Pharmaceutical Holding Company Ltd
  • Biohit Oyj
  • Biolink Life Sciences Inc
  • Biophore India Pharmaceuticals
  • Biophysical Mind Technologies Ltd
  • Bioscientia Institut für Medizinische Diagnostik GmbH
  • Biovail Laboratories Inc
  • Birch Point Medical Inc
  • Bite Tech Inc
  • BKK MTU
  • BKK Public
  • Bluefish Pharma GmbH
  • Blueprint Genetics
  • Boehringer Ingelheim International GmbH
  • Boots Company
  • Boston Scientific Corporation
  • Botulinum Toxin Research Associates Inc
  • Bouchara SA
  • Braincool AB
  • Bristol-Myers Squibb Company
  • Bruker BioSpin Corporation
  • BTG Ltd
  • California Medical Clinic for Headache
  • Capnia Inc
  • Casa Espirita Terra de Ismael
  • Case Western University of Cleveland
  • Catalent Pharma Solutions
  • Cefaly Technology sprl
  • CeGat GmbH
  • Celesio AG
  • Cellix Bio Private Ltd
  • Centogene AG
  • Centre Hospitalier Universitaire de Nice
  • Cephalon
  • Chemo Sero Therapeutic Research Institute
  • Children's Hospital Medical Center Molecular Genetics Laboratory
  • Chordate Medical AB
  • Cima Labs Inc
  • Cipla Ltd
  • Cleveland Clinic Foundation
  • CoLucid Pharmaceuticals
  • Combinatorx Inc
  • Concert Pharmaceuticals Inc
  • Concordia Pharmaceuticals Inc
  • Corcept Therapeutics Inc
  • Cosci Medical Technology Company Ltd
  • CR Double-Crane Pharmaceuticals Co
  • Crystal Pharma
  • Cubist Pharmaceuticals
  • Cumberland Pharmaceuticals Inc
  • CVS Pharmacy
  • Cyalume Speciality Products (JFC Technologies)
  • Cyberonics Inc
  • Cydex Pharmaceuticals Inc
  • Dae Woong Pharma
  • Danish Headache Center
  • Dantec Dynamics Ltd
  • DDC Clinic Molecular Diagnostics Laboratory
  • Dent Neurologic Institute (Dent Neuroscience Research Center)
  • Depomed Inc
  • Diapharm GmbH & Co
  • Diatide Inc
  • Dipharma SPA
  • DJO LLC
  • Dr. Healthcare España SL.
  • Dr. Reddy’s Laboratories Ltd.
  • Dr. Willmar Schwabe GmbH & Co. KG. 
  • Drexel University College of Medicine in Philadelphia
  • Duramed Research
  • EasyDNA
  • Ecole Polytechnique Federale de Lausanne
  • Egalet Ltd
  • Eisai Inc
  • Elan Pharma International Ltd
  • ElectroCore LLC
  • Electromedical Products International Inc
  • Eli Lilly
  • Emcure Pharmaceuticals Ltd
  • Emerillon Therapeutics Inc
  • EMKinetics Inc
  • Emory University
  • Emra-Med Arzneimittel GmbH
  • Endo International plc
  • eNeura Inc
  • Enhanced Pharmaceuticals
  • Enzo Nutraceuticals Ltd
  • Epirus Biopharmaceuticals
  • ErgoNex Pharma GmbH
  • Ethicon Inc
  • Eurand Inc
  • Euro Celtique SA
  • Evoke Pharma Inc
  • Exodos Life Sciences Ltd Partnership
  • Fabbrica Italiana Sintetici Spa
  • Faculté de Médecine Lariboisière
  • Farmalider SA
  • FGK Clinical Research GmbH
  • Fisher Wallace Laboratories
  • Forest Laboratories, Inc
  • Fuji Electric Company Ltd
  • Fundación Migraña
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • G. D. Searle LLC.
  • Gadea Grupo Farmacéutico
  • Galderma AS
  • Gemeinschaftspraxis für Humangenetik
  • General Electric
  • Generica KG
  • Generics UK Ltd
  • Genesis Bioscience SRL
  • Genetische Beratung und Diagnostik Paxis und Labor Dr
  • Georgetown University
  • Geron Corporation
  • GlaxoSmithkline plc
  • Glenmark Generics Ltd
  • Glostrup Hospital
  • Goedecke Aktiengesellschaft
  • Griffith University
  • Gruenenthal GmbH
  • Grupo Ferrer International, S
  • Guilford Pharmaceuticals Inc
  • Hammersmith Hospital
  • Head Balance Sarl
  • Hecus X-Ray Systems GmbH
  • Hennig Arzneimittel GmbH & Co
  • Heptares Therapeutics Ltd
  • Heumann Pharma GmbH & Co
  • Hexal AG
  • Hisamitsu Pharmaceutical Co
  • Hoechst AG
  • Hoffmann-La Roche (F Hoffmann-LaRoche AG)
  • Horizon Pharma plc
  • Hormosan Pharma GmbH
  • Hospital Israelita Albert Einstein
  • Hugel Inc
  • Human Genome Sciences
  • Humangenetik Bochum of the Ruhr-Universität Bochum
  • Humangenetische Praxis Osnabrück
  • Hunan Province Xiangzhong Pharmaceutical Company Ltd
  • Huntington Medical Research Institute
  • Idexx laboratories Inc
  • Illumina Inc
  • IMR
  • IMS Health
  • Imtox Privatinstitut für Immunbiologische Forschung
  • Ind-Swift Laboratories Ltd
  • InfectoPharm Arzneimittel u. Consilium GmbH.
  • Inke SA
  • Institut Allergosan Deutschland GmbH
  • Institut für Klinische Genetik Bonn
  • Institut National de la Santé et de la Recherche Médicale
  • Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
  • IntelGenx Corp
  • International Biosciences
  • International Headache Society
  • Invitae Corp
  • IPR Pharmaceuticals Inc
  • Ipsen Pharmaceuticals
  • IQVIA
  • Isis Innovation Ltd
  • Italfarmaco SpA
  • Ivax International
  • Janssen Pharmaceutica
  • Johns Hopkins University
  • Johnson & Johnson
  • Jubilant Life Sciences Ltd
  • Jubilant Organosys Ltd
  • Kaufmännische Krankenkasse (KKH)
  • KBBY LLC
  • Keller Dental Lab
  • Kiowa Hakko Kirin Co
  • Kiowa Hakko Kogyo KK
  • Knight Diagnostic Laboratories
  • Kobayashi Consumer Products LLC
  • Kobayashi Pharmaceutical Ltd
  • Koninkiljke Philips Electronics NV
  • Kos Pharmaceuticals Inc
  • Kowa Company Ltd
  • Krewel Meuselbach GmbH
  • Kydes Pharmaceuticals LLC
  • Kyowa Hakko Kogyo KK
  • La Charité - Universitätsmedizin
  • Laboratoires Boiron
  • Laboratori Baldacci S
  • Laboratorios Dr
  • Labrys Biologics Inc
  • Labtec GmbH
  • Lanco Biosciences
  • Laurus Labs Private Ltd
  • Laval University
  • Leiden University Medical Center
  • Lifesplice Pharma LLC
  • Lilly Corporate Center
  • Lion Corporation
  • Lipopharm Inc
  • LivaNova plc
  • LMU Klinikum der Universität München - Campus Großhadern
  • Lotus Pharmaceutical Co
  • LTD Liability Company Konsortsium-Pik
  • LTS Lohmann Therapie-Systeme AG
  • Luco Hybrid OSA Appliance Inc
  • Luitpold Pharmaceuticals Inc
  • Lunan Pharmaceuticals
  • Lundbeck & Co
  • Lupin Atlantis Holdings SA
  • Lupin Ltd
  • MagVenture A/S
  • Manhattan Pharmaceuticals Inc
  • Manistee Partners LLC
  • MAP Pharmaceuticals
  • Massachussets General Hospital
  • Massachussetts Institute of Technology
  • Matrix Laboratories Ltd
  • Matrixx Initiatives Inc
  • Maver SA de CV
  • Mayo Clinic
  • McKesson AG
  • McLean Hospital Corporation
  • Meda AB
  • MEDI Inc
  • Medical College of Wisconsin
  • Medical Neurogenetics LLC
  • Medical Research Council
  • Medicam Health Science srl
  • MediciNova Inc
  • Meditor Pharmaceuticals Ltd
  • Medizinisch Genetisches Zentrum München
  • Medotech AS
  • Medtronic plc
  • Medytox Inc
  • Menarini Laboratories
  • Merck & Co
  • Merck Sharp & Dohme
  • Meridian Medical Technologies, Inc
  • Merz Pharma GmbH & Co
  • Micro Laboratories Ltd
  • Micron Devices LLC
  • Migco Ltd
  • Migraine Management Ltd
  • Milestone Pharmaceutical Inc
  • Mindlife Ltd
  • Mindscope Inc
  • Minnesota Mining and Manufacturing Company
  • Mist Pharmaceuticals
  • MonoSol Rx LLC
  • Montefiore Medical Center
  • Morton Grove Pharmaceuticals Inc
  • MPA Pharma GmbH
  • Mundipharma Medical GmbH
  • Mylan Laboratories Ltd
  • Myriad Genetics Inc
  • Natco Pharma Ltd
  • National Center for Health Statistics
  • National Dentex Corporation
  • National Headache Foundation
  • Naurex Inc
  • Nautilus Neuroscience
  • Nektar Therapeutics UK Ltd
  • NeuraLieve Inc
  • NeurAxon Pharma Inc
  • Neuraxpharm Arzneimittel
  • Neuro-Fitness LLC
  • Neurobiotec GmbH
  • Neurolief Ltd
  • Neuromolecular Pharmaceuticals Inc
  • Neuronetics Inc
  • Neuropace Inc
  • NeuroSigma Inc
  • Neurotherapeutics Pharma Inc
  • Nevro Corp
  • NexGen Biomedical Inc
  • Nico Worldwide Inc
  • Nippon Zoki Pharmaceutical Company
  • Nordic Bioscience A/S
  • Nordlandssykehuset HF
  • Northwestern University
  • Norwegian University of Science and Technology
  • NovaDel Pharma Inc
  • Novartis AG
  • Novo Nordisk A/S
  • Noxxom Pharma AG
  • NPS Pharmaceuticals
  • NTT Docomo Inc
  • NuPathe Inc
  • Omeros Corporation
  • Optinose US Inc
  • Oregon Health and Science University
  • Orexo AB
  • Ortho-McNeil
  • Otsuka Pharmaceutical Co
  • Ovation Pharmaceuticals Inc
  • Oxford University Innovation
  • Pamukkale University
  • Parke Davies
  • Patheon Inc
  • Pernix Therapeutics LLC
  • Perrigo Company plc
  • Pfizer Inc
  • Pharimex GmbH
  • Pharma GmbH
  • Pharmaceutical Solutions Industry Ltd
  • Pharmacia & Upjohn
  • Pharmagen Laboratories Inc
  • Pharmalyte Solutions LLC
  • Pharmaval
  • Pharmavene Inc
  • Phase 2 Discovery (P2D) Inc
  • Phoenix Pharmahandel GmbH & Co KG
  • Plus Chemicals
  • Posivisionary Solutions LLP
  • Pozen Inc
  • Praxis für Humangenetik Freiburg
  • Precision Systems Science Co
  • PreventionGenetics
  • Proethic Pharmaceuticals Inc
  • Proximagen Group plc
  • Puren Pharma GmbH & Co
  • PwC
  • Qineva GmbH
  • Questcor Pharmaceuticals Inc
  • Ragactives SL
  • Rambam Health Care Campus
  • Ramot at Tel-Aviv Univerisity Ltd
  • Raptor Pharmaceutical Corporation
  • Reckitt Benckiser Group plc
  • Recordati S
  • Redhill Biopharma Ltd
  • Research Corporation Technologies (RCT), Inc
  • Research Foundation of the City University of New York
  • Revance Therapeutics Inc
  • Rinat Neuroscience Corporation
  • Roche Holding AG
  • Rottapharm Spa
  • Royal Holloway and Bedford New College
  • RP Scherer Corporation
  • Rules Based Medicine
  • Rutgers University
  • RZN Nutraceuticals Inc
  • S4S (UK) Ltd
  • Salix Pharmaceuticals Inc
  • Salk Institute for Biological Studies
  • Salubrious Pharmaceutical LLC
  • Sandoz
  • Sankt-Gertrauden-Krankenhaus
  • Sanofi SA
  • Schering Corporation
  • Schmerzklinik Kiel
  • Schmerzzentrum Berlin
  • Scion NeuroStim LLC
  • Sea-Band Ltd
  • Sekisui Medical Co
  • SelectHealth
  • Seoul National University Hospital
  • Sepracor Inc
  • Shahid Beheshti Medical University
  • Shanghai Institute of Pharmaceutical Industry
  • Shanghai Univerisity of Traditional Chinese Medicine
  • Shanghai Zhangjiang Zhongyao Modern Preparations Engineering Research Center
  • Shanghai Zhujian Biolog Engineering Co Ltd
  • Shino-Test Corporation
  • Shionogi & Co
  • Shire Pharmaceuticals Ltd
  • Shiuida Pharmaceuticals Group Jilin Ltd
  • Sin Nippon Biomedical Laboratories, Ltd
  • SK Life Science Inc
  • Smith Kline & French
  • SMP Logic Systems LLC
  • Sociedad Andaluza para el estudio de las Enfermedades por Alimentos
  • Solstice Neurosciences LLC
  • Solvay Pharmaceuticals
  • Somaxon Pharmaceuticals Inc
  • Sony Corporation
  • Sosei Company Ltd
  • South Miami Pharmacy
  • Spectral Dimensions Inc
  • Sphingo Tec GmbH
  • SS Pharmaceutical Co
  • St Jude Medical Inc
  • Stada AG International
  • Stanford University
  • StimRelieve LLC
  • Stimwave Technologies Inc
  • STX Med sprl
  • Suda Ltd
  • Suda Pharmaceuticals Ltd
  • Suheung Capsule Co Ltd
  • Sumitomo Dainippon Pharma Co
  • Sun Pharmaceutical Industries Ltd
  • Sunstar Suisse SA
  • Supernus Pharmaceuticals
  • Synthon BV
  • Syntilla Medical LLC
  • Takeda Pharmaceutical Company Ltd
  • Taro Pharmaceuticals
  • Taylor Pharmaceuticals
  • Teikoku Pharma USA Inc
  • Teikoku Seyyaku KK
  • Terumo Corp
  • tesa Labtec GmbH
  • Teva Pharmaceutical Industries Ltd
  • TG Therapeutics
  • The Daily Migraine LLC
  • The Michael J
  • The Ministry of Science, Technology and Innovation, Denmark
  • The Tapemark Company
  • Theranica Bio-Electronics Ltd
  • Therapeutic Solutions International, Inc
  • Thermo Fisher Scientific Inc
  • Thomas Jefferson University
  • Tian Medical, Inc
  • TMJ Health LLC
  • Tonica Elektronik A/S
  • Tonix Pharma Holdings Ltd
  • Topcon Medical Systems Inc
  • Torrent Pharmaceutical Ltd
  • TorreyPines Therapeutics
  • TPG Biotech
  • Transform Pharmaceuticals Inc
  • Travanti Pharma Inc
  • Trigemina, Inc
  • TrioxBio Inc
  • UCB SA
  • Ultramind International Ltd
  • UMD Inc
  • Univerisity of Chicago
  • Universite Victor Segalen-Bordeaux 2
  • University College London Hospital
  • University of Adelaide
  • University of Alberta
  • University of Auckland
  • University of Belfast
  • University of California San Francisco Medical School
  • University of Cincinnati School of Medicine
  • University of Gent
  • University of Glasgow
  • University of Hong Kong Chinese
  • University of Iowa
  • University of Kansas
  • University of London
  • University of Medicine and Dentistry New Jersey
  • University of Munich
  • University of Pittsburgh
  • University of South Florida
  • University of Texas Southwestern Medical Center
  • University of Texas
  • University of Toronto
  • University of Tromso
  • University of Utah Research Foundation
  • University of Zuerich
  • UPSA Laboratories
  • Upsher-Smith Laboratories Inc
  • US Department of Veterans Affairs
  • US Worldmeds LLC
  • USV Ltd
  • Valeant Pharmaceuticals International Inc
  • Valencell Inc
  • Vapharma International spa
  • Vectus Biosystems Ltd
  • Velocimed Inc
  • Vernalis Ltd
  • Vertex Pharmaceuticals Inc
  • Viatris GmbH
  • Virotex Corporation
  • Vita Cientifica, SL
  • Vitalsines International Inc
  • VR1 Inc.
  • Walgreens Boots Alliance, Inc
  • Watson Laboratories Inc
  • Weber & Weber GmbH & Co
  • Weston Medical Ltd
  • Wiewelhove GmbH
  • Winston Laboratories Inc
  • Wockhardt Ltd
  • World Health Organization
  • Wuhan Humanwell Pharmaceutical Co
  • XenoPort Inc.
  • Xoc Pharmaceuticals Inc
  • Yale University
  • Yukong Ltd
  • Zalicus Pharmaceuticals Ltd
  • Zentiva AS
  • Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ)
  • Zogenix Inc.
  • Zweigniederlassung der synlab MVZ Mannheim GmbH
  • Zydus Pharmaceuticals USA Inc

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Market for Pain Management Drugs and Devices - Product Image

Global Market for Pain Management Drugs and Devices

  • Report
  • 171 Pages
  • Global
From
Europe Companion Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029 - Product Image

Europe Companion Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

  • Report
  • 90 Pages
  • Europe
From
Smoke Evacuation Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Smoke Evacuation Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 114 Pages
  • Global
From
Global Surgical Smoke Evacuation Systems Market 2023-2027 - Product Image

Global Surgical Smoke Evacuation Systems Market 2023-2027

  • Report
  • 168 Pages
  • Global
From
Global Electrosurgery Market by Product (Monopolar, Bipolar Instrument, Generator, Smoke Evacuation System, Electrode), Surgery (Obstetrics, Cardiovascular, General, Orthopedic, Oncology, Neurosurgery, Cosmetic), and End User (Hospital, ASC) - Forecast to 2031 - Product Image

Global Electrosurgery Market by Product (Monopolar, Bipolar Instrument, Generator, Smoke Evacuation System, Electrode), Surgery (Obstetrics, Cardiovascular, General, Orthopedic, Oncology, Neurosurgery, Cosmetic), and End User (Hospital, ASC) - Forecast to 2031

  • Report
  • 226 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.